The manufacturing of pharmaceuticals also produces wastes, mainly wastewaters (WWs). These WWs must be responsibly managed. Sometimes, the organic contents of these WWs are not easily removable in standard WW treatment, hence technical options must be investigated to pretreat such WWs in order to remove or destroy the recalcitrant compounds, mostly the active pharmaceutical ingredients themselves.
View Article and Find Full Text PDFAnaerobic treatment of wastewater and waste organic solvents originating from the pharmaceutical and chemical industries was tested in a pilot anaerobic membrane bioreactor, which was operated for 580days under different operational conditions. The goal was to test the long-term treatment efficiency and identify inhibitory factors. The highest COD removal of up to 97% was observed when the influent concentration was increased by the addition of methanol (up to 25gL as COD).
View Article and Find Full Text PDFThe biotechnological production of pharmaceutical active substances needs ancillary substances. Surfactants are used at the end of the cell culture as a protection against potential viral or bacterial contamination and to lyse the producing cells for isolation and purification of the products. To find a replacement for a surfactant that had raised environmental concern, environmentally relevant data for potential alternatives were searched for in the literature.
View Article and Find Full Text PDFAn increasing number of pharmaceutical active substances are produced through biotechnological processes. For sustained and safe growth of the host organisms as well as optimal expression, purification, and formulation of the product, biotechnological manufacturing processes need optimal and robust environmental conditions, which are attained through the use of buffers, chelators, and antibiotics, beside nutrients. These ancillary substances are drained with the wastewater to a wastewater treatment plant (WWTP) and are released after treatment with the effluent to receiving waters.
View Article and Find Full Text PDFThis Account records work carried out in our laboratories during the last 2 decades in the field of enantioselective heterogeneous hydrogenation. Of particular interest was Orito's catalytic system, platinum catalysts modified with cinchona alkaloids for the hydrogenation of activated ketones. Described are the development of the optimal platinum catalyst and modifier and the expansion of the scope of the catalyst.
View Article and Find Full Text PDFIn the asymmetric hydrogenation of unfunctionalized olefins with cationic iridium-PHOX catalysts, the reaction kinetics and, as a consequence, catalyst activity and productivity depend heavily on the counterion. A strong decrease in the reaction rate is observed in the series [Al[OC(CF3)3]4]- >BArF- >[B(C6F5)4]- >PF6- >>BF4- >CF3SO3-. With the first two anions, high rates, turnover frequencies (TOF >5000 h(-1) at 4 degrees C), and turnover numbers (TONs) of 2000-5000 are routinely achieved.
View Article and Find Full Text PDFThe parallel carbonylation of aryl halides with 6-25 bar of CO in 1-mL vials in a standard autoclave was investigated. 4-Bromoacetophenone and 2-chloropyridine were used as model substrates with 102 different O-nucleophiles (primary and secondary alcohols, phenols). No inertization during the loading was necessary.
View Article and Find Full Text PDFPalladacycle dimers possessing bridging halides can be easily cleaved by using N-heterocyclic carbenes (NHCs) to generate novel monomeric complexes. The structure of one of these was determined by single-crystal diffraction study and consists of a square-planar coordination around the palladium center where the NHC ligand is trans to the amine of the palladacycle. The complex was found to be equally active in aryl amination and alpha-arylation of ketones even at very low catalyst loading (0.
View Article and Find Full Text PDF